Cis-Diamminedichloroplatinum Ii

Urethra Cancer

Jonsson Comprehensive Cancer CenterSmall moleculePhase 1/2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

15 Active assets in the Urethra Cancer cohort.

Asset / Sponsor	Phase	Rating
Vinflunine Dr Anders Ullén	Phase 2	BB
Carboplatin Jonsson Comprehensive Cancer Center	Phase 2	BB
Trastuzumab National Cancer Institute (NCI)	Phase 2	B
Pembrolizumab Emory University	Phase 2	B
Nivolumab M.D. Anderson Cancer Center	Phase 2	B

View all 29 →

Same molecule, other indications

Cis-Diamminedichloroplatinum Ii is also rated in:

squamous cell lung carcinomaActive

BBB

Indicative · Phase 4

78 / 100

primary peritoneal carcinomaActive

BBB

Indicative · Phase 3

77 / 100

adenocarcinomaActive

BBB

Indicative · Phase 4

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.